<DOC>
	<DOCNO>NCT00002965</DOCNO>
	<brief_summary>RATIONALE : Interferon alfa may interfere growth cancer cell . PURPOSE : Phase II trial study effectiveness interferon alfa treat patient recurrent unresectable meningioma malignant meningioma .</brief_summary>
	<brief_title>Interferon Alfa Treating Patients With Recurrent Unresectable Meningiomas Malignant Meningiomas</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate efficacy recombinant interferon alpha ( IFN alpha ) single agent treatment recurrent unresectable meningioma malignant meningioma . - Determine nature extent central nervous system ( CNS ) toxicity associate use alpha interferon current dose schedule . OUTLINE : This two arm , randomize study . The first arm include histologically benign meningioma . The second arm include pathology . All patient receive INF alpha subcutaneous injection Monday Friday 8 week . Treatment continue without interruption long tumor recurrence progression toxicity acceptable . Treatment continue without dose adjustment first 8 week long toxic effect grade III great . Dosage subsequent course one dose level dose produce toxicity grade III great . PROJECTED ACCRUAL : 20 patient enter per year arm .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Meningioma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven tumor : Unresectable meningioma Atypical meningioma Malignant meningioma Angioblastic meningioma Hemangiopericytoma Recurrent progressive , unresectable tumor fail radiation therapy refuse radiation therapy follow 2 surgery PATIENT CHARACTERISTICS : Age : 16 Performance status : Karnofsky least 60 % Life expectancy : At least 3 month Hematopoietic : AGC least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : SGPT le 2.0 time normal Alkaline phosphatase less 2.0 time normal Bilirubin le 1.5 mg/dL Renal : BUN le 1.5 time normal OR Creatinine le 1.5 time normal Other : No active infection No diseases obscure toxicity dangerously alter drug metabolism No serious intercurrent medical illness Not pregnant Fertile patient must use adequate contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : Prior chemotherapy allow recovered myelotoxicity secondary therapy Endocrine therapy : Prior hormonal therapy allow No concurrent hormonal therapy Radiotherapy : Prior radiotherapy allow Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
</DOC>